Background: This study aimed to evaluate the differences between simultaneous integrated boost whole-brain radiotherapy (SIB-WBRT) and brain metastases local irradiation efficacy, and determine predictors of outcomes for lung cancer brain metastases patients in therapy.
Methods: This retrospective analysis evaluated patients with brain metastases treated with SIB-WBRT (whole brain at 40 Gy/20 fractions, tumor boosted to 56–60 Gy/20 fractions) and localized irradiation (prescribed doses ranging from 20–60 Gy over 2–25 fractions, typically administered as 30 Gy/5 fractions, with a biologically effective dose [BED] of 28–100.8 Gy) at PUMCH between September 2015 and December 2021. The primary outcome was intracranial progression-free survival (iPFS), with secondary outcomes encompassing overall survival (OS), development of new intracranial lesions, and tumor control. Propensity score matching was employed to compare the two retrospective groups. Survival curves for iPFS, OS, new intracranial lesions, and tumor control were generated and estimated using the Kaplan-Meier approach. Cox proportional hazards modeling was applied to examine the relationships between pertinent variables and clinical outcomes.
Results: After Propensity score matching, 59 patients were enrolled in each group (SIB-WBRT and local irradiation), with a total of 118 patients included in the analysis. No significant difference was observed between the 2 groups in iPFS (HR = 0.8, 95%CI: 0.4-1.3, P = 0.288), OS (HR = 1.1, 95%CI: 0.7-1.8, P = 0.653), or incidence of intracranial new lesions (HR = 0.6, 95%CI: 0.4-1.2, P = 0.144). However, a statistically significant difference was noted in local control time between the groups, with local irradiation brain metastases being superior (HR = 0.4, 95% CI: 0.2-0.8, P = 0.005). Tumor volume and other factors were related to local control.
Conclusion: Compared to local irradiation, SIB-WBRT did not significantly improve iPFS in patients with brain metastases. Compared to SIB-WBRT, local irradiation improved local control. Tumor volume and other factors may be associated with local control.
| [1] |
Horbinski C, Nabors LB, Portnow J, et al. NCCN Guidelines® Insights: Central Nervous System Cancers, Version 2.2022. J Natl Compr Canc Netw. 2023;21(1):12-20.
|
| [2] |
Bi Q, Lian X, Shen J, Zhang F, Xu T. Exploration of radiotherapy strategy for brain metastasis patients with driver gene positivity in lung cancer. J Cancer. 2024;15(7):1994-2002.
|
| [3] |
Mathew G, Agha R, Albrecht J, et al. STROCSS 2021: Strengthening the reporting of cohort, cross-sectional and case-control studies in surgery. Int J Surg. 2021;96:106165.
|
| [4] |
Bostel T, Akbaba S, Wollschläger D, et al. Chemoradiotherapy in geriatric patients with squamous cell carcinoma of the esophagus: Multi-center analysis on the value of standard treatment in the elderly. Front Oncol. 2023;13:1063670.
|
| [5] |
Loesch D, Robert N, Jones S, Elkordy M, Ilegbodu D, Asmar L. Phase II Trial of a Novel Paclitaxel Schedule As Single-Agent, First-Line Therapy for HER-2/neu-Negative Metastatic Breast Cancer: A Community-Based Study. J Oncol Pract. 2006;2(6):268-273.
|
| [6] |
van Loon J, Grutters J, Wanders R, et al. Follow-up with 18FDG-PET-CT after radical radiotherapy with or without chemotherapy allows the detection of potentially curable progressive disease in non-small cell lung cancer patients: a prospective study. Eur J Cancer. 2009;45(4):588-595.
|
| [7] |
Hsu CN, Tain YL, Lu PC, Lin HW. Comparisons of EQ-5D-Y and PedsQL in pediatric patients with mild-to-moderate chronic kidney disease in longitudinal analyses. Health Qual Life Outcomes. 2023;21(1):117.
|
| [8] |
Pirzkall A, Debus J, Lohr F, et al. Radiosurgery alone or in combination with whole-brain radiotherapy for brain metastases. J Clin Oncol. 1998;16(11):3563-3569.
|
| [9] |
Oudard S, Elaidi RT. Sequential therapy with targeted agents in patients with advanced renal cell carcinoma: optimizing patient benefit. Cancer Treat Rev. 2012;38(8):981-987.
|
| [10] |
Matsuo T, Shibata S, Yasunaga A, et al. Dose optimization and indication of Linac radiosurgery for brain metastases. Int J Radiat Oncol Biol Phys. 1999;45(4):931-939.
|
| [11] |
Sneed PK, Lamborn KR, Forstner JM, et al. Radiosurgery for brain metastases: is whole brain radiotherapy necessary? Int J Radiat Oncol Biol Phys. 1999;43(3):549-558.
|
| [12] |
Kocher M, Soffietti R, Abacioglu U, et al. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952–26001 study. J Clin Oncol. 2011;29(2):134-141.
|
| [13] |
Rades D, Schild SE. Do patients with a limited number of brain metastases need whole-brain radiotherapy in addition to radiosurgery? Strahlenther Onkol. 2012;188(8):702-706.
|
| [14] |
Aoyama H, Shirato H, Tago M, et al. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA. 2006;295(21):2483-2491.
|
| [15] |
Chougule P, Burton-Williams M, Saris S, et al. Randomized treatment of brain metastasis with gamma knife radiosurgery, whole brain radiotherapy or both. Int J Radiat Oncol Biol Phys. 2000;3(48):114.
|
| [16] |
Brown PD, Jaeckle K, Ballman KV, et al. Effect of Radiosurgery Alone vs Radiosurgery With Whole Brain Radiation Therapy on Cognitive Function in Patients With 1 to 3 Brain Metastases: A Randomized Clinical Trial. JAMA. 2016;316(4):401-409.
|
| [17] |
Chaung KV, Sloan AE, Choi S. Limited brain metastases: a narrative review. Ann Palliat Med. 2021;10(5):6016-6027.
|
| [18] |
Redmond KJ, Gui C, Benedict S, et al. Tumor Control Probability of Radiosurgery and Fractionated Stereotactic Radiosurgery for Brain Metastases. Int J Radiat Oncol Biol Phys. 2021;110(1):53-67.
|
| [19] |
Bi Q, Shen J, Li P, Zeng Y, Lian X, Zhang F. Efficacy of Whole-Brain Radiotherapy Plus Simultaneous Integrated Boost (SIB-WBRT) for Lung Cancer Brain Metastases. J Cancer. 2024;15(14):4636-4642.
|
RIGHTS & PERMISSIONS
2025 The Author(s). Precision Radiation Oncology published by John Wiley & Sons Australia, Ltd on behalf of Shandong Cancer Hospital & Institute.
PDF
